DK3532103T3 - Formuleringer af lipid-nanopartikler - Google Patents

Formuleringer af lipid-nanopartikler

Info

Publication number
DK3532103T3
DK3532103T3 DK17800986.6T DK17800986T DK3532103T3 DK 3532103 T3 DK3532103 T3 DK 3532103T3 DK 17800986 T DK17800986 T DK 17800986T DK 3532103 T3 DK3532103 T3 DK 3532103T3
Authority
DK
Denmark
Prior art keywords
lipid nanoparticle
nanoparticle formulations
formulations
lipid
nanoparticle
Prior art date
Application number
DK17800986.6T
Other languages
English (en)
Inventor
Barbara Mui
Christopher Barbosa
Thomas Madden
Xinyao Du
Michael J Hope
Paulo Jia Ching Lin
Steven M Ansell
Original Assignee
Acuitas Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/337,434 external-priority patent/US10166298B2/en
Application filed by Acuitas Therapeutics Inc filed Critical Acuitas Therapeutics Inc
Application granted granted Critical
Publication of DK3532103T3 publication Critical patent/DK3532103T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK17800986.6T 2016-10-26 2017-10-26 Formuleringer af lipid-nanopartikler DK3532103T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662413319P 2016-10-26 2016-10-26
US15/337,434 US10166298B2 (en) 2015-10-28 2016-10-28 Lipids and lipid nanoparticle formulations for delivery of nucleic acids
US201762485836P 2017-04-14 2017-04-14
US201762485833P 2017-04-14 2017-04-14
PCT/US2017/058619 WO2018081480A1 (en) 2016-10-26 2017-10-26 Lipid nanoparticle formulations

Publications (1)

Publication Number Publication Date
DK3532103T3 true DK3532103T3 (da) 2026-03-02

Family

ID=62025447

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17800986.6T DK3532103T3 (da) 2016-10-26 2017-10-26 Formuleringer af lipid-nanopartikler

Country Status (4)

Country Link
EP (2) EP3532103B1 (da)
DK (1) DK3532103T3 (da)
FI (1) FI3532103T3 (da)
WO (1) WO2018081480A1 (da)

Families Citing this family (267)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3766916T (pt) 2014-06-25 2022-11-28 Acuitas Therapeutics Inc Novos lípidos e formulações de nanopartículas lipídicas para distribuição de ácidos nucleicos
ES2910425T3 (es) 2015-09-17 2022-05-12 Modernatx Inc Compuestos y composiciones para la administración intracelular de agentes terapéuticos
WO2017075531A1 (en) 2015-10-28 2017-05-04 Acuitas Therapeutics, Inc. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
CA3007297A1 (en) 2015-12-22 2017-06-29 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
WO2017117528A1 (en) * 2015-12-30 2017-07-06 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
US12491261B2 (en) 2016-10-26 2025-12-09 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
EP3538067A1 (en) 2016-11-08 2019-09-18 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
RS63953B1 (sr) 2017-03-15 2023-02-28 Modernatx Inc Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava
JP7332478B2 (ja) 2017-03-15 2023-08-23 モデルナティエックス インコーポレイテッド 脂質ナノ粒子製剤
EP3596042B1 (en) 2017-03-15 2022-01-12 Modernatx, Inc. Crystal forms of amino lipids
US12077501B2 (en) 2017-06-14 2024-09-03 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
US11524932B2 (en) 2017-08-17 2022-12-13 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
MX2020002348A (es) 2017-08-31 2020-10-08 Modernatx Inc Métodos de elaboración de nanopartículas lipídicas.
CA3092497A1 (en) 2018-03-19 2019-09-26 Crispr Therapeutics Ag Novel rna-programmable endonuclease systems and uses thereof
JP7410135B2 (ja) * 2018-09-19 2024-01-09 モデルナティエックス インコーポレイテッド 治療薬の細胞内送達のための化合物及び組成物
WO2020061457A1 (en) * 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
AU2019361129A1 (en) 2018-10-18 2021-05-20 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
JP7564102B2 (ja) 2018-11-28 2024-10-08 クリスパー セラピューティクス アクチェンゲゼルシャフト ＬＮＰでの使用に最適化された、ＣＡＳ９をコードするｍＲＮＡ
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
BR112021014845A2 (pt) * 2019-01-31 2021-11-03 Modernatx Inc Métodos de preparação de nanopartículas lipídicas
EP3937963B1 (en) 2019-03-12 2025-05-07 CRISPR Therapeutics AG Novel high fidelity rna-programmable endonuclease systems and uses thereof
UA129330C2 (uk) * 2019-08-14 2025-03-19 Акітас Терап'Ютікс, Інк. Поліпшені ліпідні наночастинки для доставляння нуклеїнових кислот
CA3154618A1 (en) 2019-09-19 2021-03-25 Modernatx, Inc. Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
CN114391040A (zh) 2019-09-23 2022-04-22 欧米茄治疗公司 用于调节载脂蛋白b(apob)基因表达的组合物和方法
US11987791B2 (en) 2019-09-23 2024-05-21 Omega Therapeutics, Inc. Compositions and methods for modulating hepatocyte nuclear factor 4-alpha (HNF4α) gene expression
CR20220220A (es) 2019-11-18 2022-09-20 Janssen Biotech Inc Vacunas basadas en calr y jak2 mutantes y sus usos
EP4076647A1 (en) * 2019-12-20 2022-10-26 CureVac AG Lipid nanoparticles for delivery of nucleic acids
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
WO2021167703A1 (en) * 2020-02-19 2021-08-26 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing tgfb antagonist prodrugs useful in the treatment of cancer and methods thereof
AU2021234302A1 (en) 2020-03-11 2022-11-10 Omega Therapeutics, Inc. Compositions and methods for modulating forkhead box p3 (foxp3) gene expression
AU2021250814A1 (en) 2020-03-30 2022-10-13 BioNTech SE RNA compositions targeting Claudin-18.2
JP2023522249A (ja) * 2020-04-22 2023-05-29 ビオンテック・ソシエタス・エウロパエア コロナウイルスワクチン
MX2022014653A (es) 2020-05-20 2023-02-16 Flagship Pioneering Innovations Vi Llc Composiciones de antigeno de coronavirus y sus usos.
CA3179444A1 (en) 2020-05-20 2021-11-25 Avak Kahvejian Immunogenic compositions and uses thereof
US20230203510A1 (en) 2020-05-29 2023-06-29 Flagship Pioneering Innovations Vi, Llc Trem compositions and methods relating thereto
WO2021243301A2 (en) 2020-05-29 2021-12-02 Flagship Pioneering Innovations Vi, Llc. Trem compositions and methods relating thereto
WO2025056938A1 (en) 2023-09-11 2025-03-20 BioNTech SE Rna compositions for delivery of incretin agents
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
KR20230051181A (ko) * 2020-07-13 2023-04-17 어드밴식스 레진즈 앤드 케미컬즈 엘엘씨 건강관리 제품에 사용하기 위한 분지형 아미노산 계면활성제
JP2023542492A (ja) 2020-09-03 2023-10-10 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー 免疫原性組成物及びその使用
CZ310613B6 (cs) 2020-09-23 2026-01-28 Ústav organické chemie a biochemie AV ČR, v. v. i. Lipidoidy pro transfekci nukleových kyselin a jejich použití
JP2023546175A (ja) 2020-10-14 2023-11-01 ジョージ・メイソン・リサーチ・ファウンデーション・インコーポレイテッド 脂質ナノ粒子製造の方法及びそれに由来する組成物
WO2022099003A1 (en) 2020-11-06 2022-05-12 Sanofi Lipid nanoparticles for delivering mrna vaccines
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
CN117098541A (zh) 2020-11-25 2023-11-21 阿卡格拉医药公司 用于递送核酸的脂质纳米粒及相关使用方法
US11918643B2 (en) 2020-12-22 2024-03-05 CureVac SE RNA vaccine against SARS-CoV-2 variants
AU2021409740A1 (en) 2020-12-23 2023-07-06 Flagship Pioneering Innovations Vi, Llc Compositions of modified trems and uses thereof
AU2022245247A1 (en) * 2021-03-24 2023-10-05 Modernatx, Inc. Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
WO2022204369A1 (en) * 2021-03-24 2022-09-29 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
CA3214085A1 (en) 2021-03-31 2022-10-06 Darby Rye Schmidt Thanotransmission polypeptides and their use in treating cancer
US20240180951A1 (en) * 2021-04-08 2024-06-06 Xiamen Sinopeg Biotech Co., Ltd. Pegylated lipid, liposome modified by the lipid, pharmaceutical composition containing the liposome, formulation and application thereof
DK4319803T3 (da) 2021-04-08 2025-12-15 Vaxthera Sas Coronavirusvaccine omfattende et mosaikprotein
US20240226132A1 (en) 2021-04-12 2024-07-11 BioNTech SE Rna compositions comprising a buffer substance and methods for preparing, storing and using the same
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
AU2022271249A1 (en) 2021-05-04 2023-11-16 BioNTech SE Immunogen selection
CA3215963A1 (en) 2021-05-28 2022-12-01 Yaoxin LIN Lipid compound and use thereof in delivery of nucleic acid
US20240141312A1 (en) 2021-06-11 2024-05-02 Bayer Aktiengesellschaft Type v rna programmable endonuclease systems
EP4101928A1 (en) 2021-06-11 2022-12-14 Bayer AG Type v rna programmable endonuclease systems
WO2023283359A2 (en) 2021-07-07 2023-01-12 Omega Therapeutics, Inc. Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
JP2024525795A (ja) 2021-07-15 2024-07-12 バイオエヌテック エスエー Ｃｌｄｎ６陽性癌を治療するための、ｃｌｄｎ６およびｃｄ３結合要素をコードする薬剤
CN115403761B (zh) * 2021-07-23 2025-04-25 天津键凯科技有限公司 一种多元甘醇修饰的脂质化合物及其制备方法和应用
WO2023009547A1 (en) 2021-07-26 2023-02-02 Flagship Pioneering Innovations Vi, Llc Trem compositions and uses thereof
BR112024001180A2 (pt) 2021-07-29 2024-04-30 BioNTech SE Composições e métodos para tratamento do melanoma
CN115703714B (zh) * 2021-08-13 2025-06-10 广州谷森制药有限公司 阳离子脂质化合物
CN115710191B (zh) * 2021-08-23 2025-06-10 广州谷森制药有限公司 阳离子脂质化合物
CN115710193B (zh) * 2021-08-23 2025-06-10 广州谷森制药有限公司 阳离子脂质化合物
EP4141013A1 (en) 2021-08-31 2023-03-01 Studiengesellschaft Kohle mbH Stereochemically pure lipids for nucleic acid delivery
WO2023030635A1 (en) 2021-09-02 2023-03-09 BioNTech SE Potency assay for therapeutic potential of coding nucleic acid
WO2023031855A1 (en) 2021-09-03 2023-03-09 Glaxosmithkline Biologicals Sa Substitution of nucleotide bases in self-amplifying messenger ribonucleic acids
JP2024538489A (ja) 2021-09-03 2024-10-23 キュアバック エスイー 核酸を送達するための新規な脂質ナノ粒子
EP4144841A1 (en) 2021-09-07 2023-03-08 Bayer AG Novel small rna programmable endonuclease systems with impoved pam specificity and uses thereof
CN118317944A (zh) 2021-09-14 2024-07-09 雷纳嘉德医疗管理公司 非环状脂质及其使用方法
TW202328067A (zh) 2021-09-14 2023-07-16 美商雷納嘉德醫療管理公司 環狀脂質及其使用方法
EP4464783A3 (en) 2021-09-17 2025-01-22 Flagship Pioneering Innovations VI, LLC Compositions and methods for producing circular polyribonucleotides
WO2023051926A1 (en) 2021-09-30 2023-04-06 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
AR127312A1 (es) * 2021-10-08 2024-01-10 Suzhou Abogen Biosciences Co Ltd Compuestos lipídicos ycomposiciones de nanopartículas lipídicas
KR20230053998A (ko) 2021-10-15 2023-04-24 (주)지노믹트리 mRNA 발현을 위한 유전자 구조체
TW202322826A (zh) 2021-10-18 2023-06-16 美商旗艦先鋒創新有限責任公司 用於純化多核糖核苷酸之組成物及方法
EP4238577A3 (en) 2021-10-22 2023-12-06 BioNTech SE Compositions for administration of different doses of rna
US20250027108A1 (en) 2021-10-29 2025-01-23 CureVac SE Improved circular rna for expressing therapeutic proteins
WO2023083434A1 (en) 2021-11-09 2023-05-19 BioNTech SE Rna encoding peptidoglycan hydrolase and use thereof for treating bacterial infection
KR102772764B1 (ko) 2021-11-10 2025-02-27 주식회사 에스엠엘바이오팜 트레할로즈 유도체 및 신규 구조 유지 화합물을 포함하는 핵산 의약품 전달용 지질나노입자의 약학 조성물
WO2023096990A1 (en) 2021-11-24 2023-06-01 Flagship Pioneering Innovation Vi, Llc Coronavirus immunogen compositions and their uses
US20250032604A1 (en) 2021-11-24 2025-01-30 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and their uses
KR20240125931A (ko) 2021-11-24 2024-08-20 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 수두-대상포진 바이러스 면역원 조성물 및 이의 용도
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
IL313486A (en) 2021-12-16 2024-08-01 Acuitas Therapeutics Inc Lipids for use in lipid nanoparticle formulations
WO2023115013A1 (en) 2021-12-17 2023-06-22 Flagship Pioneering Innovations Vi, Llc Methods for enrichment of circular rna under denaturing conditions
CN118679254A (zh) 2021-12-22 2024-09-20 旗舰创业创新六公司 用于纯化多核糖核苷酸的组合物和方法
MX2024007870A (es) 2021-12-23 2024-08-15 Flagship Pioneering Innovations Vi Llc Polirribonucleotidos circulares que codifican polipeptidos antifusogenicos.
US20230201817A1 (en) 2021-12-23 2023-06-29 Biontech Delivery Technologies Gmbh Modular drug production system
CA3243301A1 (en) 2021-12-23 2023-06-29 Bayer Aktiengesellschaft NEW SMALL PROGRAMMABLE TYPE V RNA ENDONUCLEASE SYSTEMS
WO2023126053A1 (en) 2021-12-28 2023-07-06 BioNTech SE Lipid-based formulations for administration of rna
CN114957027B (zh) * 2022-01-13 2023-05-19 北京悦康科创医药科技股份有限公司 一种阳离子脂质化合物、包含其的组合物及用途
IL314324A (en) 2022-01-27 2024-09-01 BioNTech SE Pharmaceutical preparations for administration of herpes simplex virus antigens and related methods
EP4469091A1 (en) 2022-01-28 2024-12-04 CureVac SE Nucleic acid encoded transcription factor inhibitors
JP2025507295A (ja) 2022-02-02 2025-03-18 バイオエヌテック エスエー 細胞への核酸の標的化送達のための薬剤および方法
WO2023148276A1 (en) 2022-02-02 2023-08-10 BioNTech SE Agents and methods for targeted delivery to cells
WO2023156487A1 (en) 2022-02-15 2023-08-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for modulating tear film composition to treat corneal defects
WO2023183369A2 (en) * 2022-03-22 2023-09-28 Respirerx Pharmaceuticals, Inc. Lipid nanoparticle compositions and methods for formulating insoluble drugs
CA3245624A1 (en) 2022-03-25 2023-09-28 Sail Biomedicines, Inc. NEW IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND THEIR METHODS OF USE
EP4504252A2 (en) 2022-04-08 2025-02-12 Flagship Pioneering Innovations VII, LLC Vaccines and related methods
AU2023260227A1 (en) 2022-04-27 2024-11-21 Shanghai Regenelead Therapies Co., Ltd Nucleic acid construct and use thereof
CA3257006A1 (en) 2022-05-09 2023-11-16 Flagship Pioneering Innovations Vi, Llc TREM COMPOSITIONS AND METHODS OF USE FOR TREATING PROLIFERATIVE DISORDERS
TW202409283A (zh) 2022-05-13 2024-03-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 雙股ｄｎａ組合物及相關方法
EP4522650A1 (en) 2022-05-13 2025-03-19 BioNTech SE Rna compositions targeting hiv
TW202400784A (zh) 2022-05-13 2024-01-01 大陸商上海瑞宏迪醫藥有限公司 包含utr的核酸構建體及其應用
AU2023275780B2 (en) 2022-05-25 2026-03-05 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
KR20250028547A (ko) 2022-05-25 2025-02-28 큐어백 에스이 대장균 FimH 항원성 폴리펩타이드를 인코딩하는 핵산 기반 백신
WO2023230295A1 (en) 2022-05-25 2023-11-30 BioNTech SE Rna compositions for delivery of monkeypox antigens and related methods
EP4518845A1 (en) 2022-05-30 2025-03-12 BioNTech SE Complexes for delivery of nucleic acids
AU2023284048A1 (en) 2022-06-10 2024-11-14 Bayer Aktiengesellschaft Novel small type v rna programmable endonuclease systems
WO2023242817A2 (en) 2022-06-18 2023-12-21 Glaxosmithkline Biologicals Sa Recombinant rna molecules comprising untranslated regions or segments encoding spike protein from the omicron strain of severe acute respiratory coronavirus-2
WO2023250112A1 (en) 2022-06-22 2023-12-28 Flagship Pioneering Innovations Vi, Llc Compositions of modified trems and uses thereof
CN114989182B (zh) * 2022-06-23 2023-06-23 尧唐(上海)生物科技有限公司 脂质化合物、包含其的组合物及应用
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
WO2024022263A1 (zh) * 2022-07-25 2024-02-01 苏州艾博生物科技有限公司 脂质化合物和脂质纳米颗粒组合物
JP2025525778A (ja) 2022-08-01 2025-08-07 フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー 免疫調節タンパク質及び関連方法
WO2024028325A1 (en) 2022-08-01 2024-02-08 BioNTech SE Nucleic acid compositions comprising amphiphilic oligo ethylene glycol (oeg)-conjugated compounds and methods of using such compounds and compositions
WO2024027910A1 (en) 2022-08-03 2024-02-08 BioNTech SE Rna for preventing or treating tuberculosis
KR20250048270A (ko) 2022-08-03 2025-04-08 비온테크 에스이 결핵 예방 및 치료를 위한 rna
EP4569112A1 (en) 2022-08-12 2025-06-18 Remix Therapeutics Inc. Methods and compositions for modulating splicing at alternative splice sites
EP4577519A1 (en) * 2022-08-23 2025-07-02 ModernaTX, Inc. Methods for purification of ionizable lipids
AU2023329397A1 (en) * 2022-08-26 2025-03-06 Renagade Therapeutics Management Inc. Pegylated lipid compounds and methods of use thereof
KR20250056256A (ko) 2022-08-31 2025-04-25 세일 바이오메디슨스, 인크. 신규 이온화성 지질 및 지질 나노입자, 그리고 이의 사용 방법
US20260076914A1 (en) * 2022-09-11 2026-03-19 Barcode Nanotech Ltd. Ionizable lipids and compositions comprising same
CN119731149A (zh) * 2022-09-19 2025-03-28 苏州盛迪亚生物医药有限公司 一种制备2-羟乙基氨基己酸酯类化合物方法及其应用
CA3267942A1 (en) 2022-09-23 2024-03-28 BioNTech SE COMPOSITIONS FOR THE ADMINISTRATION OF HEPATIC STAGE ANTIGENS AND ASSOCIATED METHODS
EP4590331A1 (en) 2022-09-23 2025-07-30 BioNTech SE Compositions for delivery of plasmodium csp antigens and related methods
WO2024063789A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of malaria antigens and related methods
WO2024063788A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of malaria antigens and related methods
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024074211A1 (en) 2022-10-06 2024-04-11 BioNTech SE Rna compositions targeting claudin-18.2
IL319682A (en) 2022-10-06 2025-05-01 BioNTech SE RNA complexes targeting claudin-18.2
GB202215200D0 (en) 2022-10-14 2022-11-30 Mercurna B V Novel ionizable lipids
WO2024083345A1 (en) 2022-10-21 2024-04-25 BioNTech SE Methods and uses associated with liquid compositions
US12186389B2 (en) 2022-10-28 2025-01-07 Glaxosmithkline Biologicals Sa Nucleic acid base vaccine against emerging SARS-CoV-2 variants
CN120513299A (zh) 2022-10-31 2025-08-19 旗舰创业创新第六有限责任公司 用于纯化多核糖核苷酸的组合物和方法
AR131008A1 (es) 2022-11-08 2025-02-05 Flagship Pioneering Innovations Vi Llc Composiciones y métodos para producir polirribonucleótidos circulares
AU2023398007A1 (en) 2022-12-13 2025-06-19 Bayer Aktiengesellschaft Engineered type v rna programmable endonucleases and their uses
TW202430215A (zh) 2022-12-14 2024-08-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 用於將治療劑遞送至骨之組成物和方法
WO2024133160A1 (en) 2022-12-19 2024-06-27 Glaxosmithkline Biologicals Sa Hepatitis b compositions
CN119095585A (zh) * 2022-12-21 2024-12-06 苏州艾博生物科技有限公司 包含固醇修饰的磷脂的脂质纳米颗粒
WO2024141955A1 (en) 2022-12-28 2024-07-04 BioNTech SE Rna compositions targeting hiv
WO2024151673A2 (en) 2023-01-09 2024-07-18 President And Fellows Of Harvard College Recombinant nucleic acid molecules and their use in wound healing
US20240252520A1 (en) 2023-01-09 2024-08-01 Beth Israel Deaconess Medical Center, Inc. Therapeutic agents and their use for treating chronic wounds
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
EP4648794A2 (en) 2023-01-09 2025-11-19 Flagship Pioneering Innovations VII, LLC Vaccines and related methods
WO2024153324A1 (en) 2023-01-18 2024-07-25 BioNTech SE Rna formulations for pharmaceutical use
WO2024155938A1 (en) * 2023-01-20 2024-07-25 Poseida Therapeutics, Inc. Lipidoid compounds and related compositions and uses
TW202438515A (zh) 2023-02-06 2024-10-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 免疫調節組合物及相關方法
WO2024165146A1 (en) 2023-02-07 2024-08-15 Biontech Cell & Gene Therapies Gmbh Immune effector cells stably and transiently expressing nucleic acids
KR20250151427A (ko) 2023-02-13 2025-10-21 플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 치료적 조성물을 위한 절단성 링커 함유 이온화 가능한 지질 및 지질 담체
TW202446956A (zh) 2023-02-17 2024-12-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 包含經修飾的胞嘧啶的ｄｎａ組成物
TW202438089A (zh) 2023-02-17 2024-10-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 包含經修飾的尿嘧啶的ｄｎａ組成物
EP4669330A1 (en) 2023-02-21 2025-12-31 Institut National de la Santé et de la Recherche Médicale METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SANFILIPPO SYNDROME TYPE IIIB
WO2024180363A1 (en) 2023-02-28 2024-09-06 BioNTech SE Linker sequence potency assays for multiple coding nucleic acids
EP4673557A1 (en) 2023-02-28 2026-01-07 BioNTech SE Linker sequence potency assays for multiple coding nucleic acids
AU2024233180A1 (en) 2023-03-08 2025-09-25 CureVac SE Novel lipid nanoparticle formulations for delivery of nucleic acids
IL322837A (en) 2023-03-09 2025-10-01 BioNTech SE Peptidoglycan hydrolases with bactericidal activity
JP2026509462A (ja) 2023-03-15 2026-03-19 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー ポリリボヌクレオチドを含む組成物及びその使用
WO2024192422A1 (en) 2023-03-15 2024-09-19 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and uses thereof
WO2024194767A1 (en) 2023-03-17 2024-09-26 BioNTech SE Automated drug production system
CN118666726A (zh) * 2023-03-17 2024-09-20 尧唐(上海)生物科技有限公司 递送治疗剂的脂质化合物及其制备方法与应用
WO2024193827A1 (en) 2023-03-23 2024-09-26 BioNTech SE Stabilized nucleic acid compositions and methods for preparing, storing and using the same
WO2024209418A1 (en) 2023-04-07 2024-10-10 BioNTech SE Heating and cooling jacket for fluid vessels
CN121219411A (zh) 2023-04-12 2025-12-26 旗舰先锋创新Vi有限责任公司 用于在错义突变的校正中使用的trem
EP4695393A1 (en) 2023-04-12 2026-02-18 Flagship Pioneering Innovations VI, LLC Modified trems, compositions, and related methods thereof
WO2024213776A1 (en) 2023-04-14 2024-10-17 BioNTech SE Rna for preventing or treating tuberculosis
AU2024255899A1 (en) 2023-04-14 2025-09-18 BioNTech SE Hiv vaccine
WO2024216212A1 (en) 2023-04-14 2024-10-17 BioNTech SE Rna for preventing or treating tuberculosis
CN121398842A (zh) 2023-04-14 2026-01-23 百欧恩泰欧洲股份公司 用于预防或治疗结核病的rna
WO2024220746A2 (en) 2023-04-21 2024-10-24 Flagship Pioneering Innovations Vii, Llc Rnai agents targeting fatty acid synthase and related methods
WO2024227433A1 (zh) * 2023-04-29 2024-11-07 康希诺(上海)生物研发有限公司 一种用于递送核酸药物的脂质纳米颗粒及其制备方法和用途
WO2024228044A1 (en) 2023-05-03 2024-11-07 BioNTech SE Optimized csp variants and related methods
WO2024228150A1 (en) 2023-05-03 2024-11-07 BioNTech SE Optimized csp variants and related methods
WO2024229309A2 (en) 2023-05-03 2024-11-07 Manifold Biotechnologies, Inc. Methodsand compositions for high-throughput protein delivery, screening, and detection
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases
DE102023001946A1 (de) 2023-05-12 2024-11-14 Friedrich-Schiller-Universität Jena, Körperschaft des öffentlichen Rechts Nanopartikel für den Transport von Wirkstoffen mit anionischen Gruppen, Verfahren zu deren Herstellung und deren Verwendung
WO2024238700A1 (en) 2023-05-15 2024-11-21 Chroma Medicine, Inc. Compositions and methods for epigenetic regulation of hbv gene expression
EP4713453A1 (en) 2023-05-15 2026-03-25 nChroma Bio, Inc. Compositions and methods for epigenetic regulation of hbv gene expression
WO2024236336A1 (en) 2023-05-17 2024-11-21 Institut National de la Santé et de la Recherche Médicale Lipc variant in the treatment of hypercholesterolemia and atherosclerotic cardiovascular disease
WO2024243438A2 (en) 2023-05-23 2024-11-28 Omega Therapeutics, Inc. Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression
KR20240170771A (ko) 2023-05-26 2024-12-04 삼성바이오로직스 주식회사 2차 또는 3차 구조를 갖는 폴리 a 테일을 포함하는 신규 핵산 구조체 및 이의 용도
WO2024258829A1 (en) 2023-06-12 2024-12-19 Flagship Pioneering Innovations Vii, Llc Sars-cov-2 vaccine compositions and related methods
WO2025006684A1 (en) 2023-06-28 2025-01-02 Flagship Pioneering Innovations Vi, Llc Circular polyribonucleotides encoding antifusogenic polypeptides
AU2024310564A1 (en) 2023-06-29 2025-11-27 BioNTech SE Modular multiplatform system for mrna drug production
CN121532514A (zh) 2023-07-07 2026-02-13 上海环码生物医药有限公司 用于季节性流感的环状rna疫苗及使用方法
WO2025021277A1 (en) 2023-07-21 2025-01-30 BioNTech SE Agents and methods for targeted delivery of cytokines to immune cells
WO2025024335A2 (en) 2023-07-21 2025-01-30 BioNTech SE Compositions for delivery of plasmodium antigens and related methods
WO2025024324A1 (en) 2023-07-21 2025-01-30 BioNTech SE Compositions for delivery of plasmodium antigens and related methods
WO2025024337A1 (en) 2023-07-24 2025-01-30 BioNTech SE Compositions for delivery of plasmodium antigens and related methods
WO2025024486A2 (en) 2023-07-25 2025-01-30 Flagship Pioneering Innovations Vii, Llc Cas endonucleases and related methods
KR20250018367A (ko) 2023-07-28 2025-02-05 한국과학기술원 히스톤 코드 리더 도메인을 포함하는 폴리펩티드 및 이의 용도
TW202519509A (zh) 2023-08-01 2025-05-16 德商拜恩技術股份公司 可離子化硫脂質及其用途
WO2025026545A1 (en) 2023-08-01 2025-02-06 BioNTech SE Ionizable thioplipids and uses thereof
WO2025026553A1 (en) 2023-08-02 2025-02-06 BioNTech SE Agents and methods for targeted delivery to cells
WO2025030154A1 (en) 2023-08-03 2025-02-06 The Trustees Of The University Of Pennsylvania Pharmaceutical compositions for delivery of herpes simplex virus glycoprotein b antigens and related methods
WO2025027576A2 (en) 2023-08-03 2025-02-06 BioNTech SE Rna compositions targeting hiv
WO2025030097A2 (en) 2023-08-03 2025-02-06 BioNTech SE Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
WO2025027579A2 (en) 2023-08-03 2025-02-06 BioNTech SE Rna compositions targeting hiv
NL2035538B1 (en) 2023-08-03 2025-02-18 Univ Eindhoven Tech Lipid-like copolymers and method of producing these and the use thereof, pharmaceutical compositions comprising said copolymers, and the use of said compositions.
WO2025032158A1 (en) 2023-08-08 2025-02-13 Institut National de la Santé et de la Recherche Médicale Method to treat tauopathies
WO2025042786A1 (en) 2023-08-18 2025-02-27 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides and uses thereof
WO2025045142A1 (en) 2023-08-29 2025-03-06 Shanghai Circode Biomed Co., Ltd. Circular rna encoding vegf polypeptides, formulations, and methods of uses
WO2025054236A2 (en) 2023-09-06 2025-03-13 Flagship Pioneering Innovations Vii, Llc Sars-cov-2 vaccine compositions and related methods
WO2025054556A1 (en) 2023-09-07 2025-03-13 BioNTech SE Rna compositions for delivery of mpox antigens and related methods
WO2025057088A1 (en) 2023-09-11 2025-03-20 BioNTech SE Rna compositions for delivery of incretin agents
CN119591513A (zh) * 2023-09-11 2025-03-11 苏州星核迪赛生物技术有限公司 局部递送药物的材料及其应用
US20250268826A1 (en) 2023-09-18 2025-08-28 Flagship Pioneering Innovations Vii, Llc Ionizable lipidoid compositions and therapeutic uses thereof
WO2025061863A1 (en) 2023-09-20 2025-03-27 BioNTech SE Method
WO2025064850A1 (en) 2023-09-22 2025-03-27 BioNTech SE Rna constructs with n-terminal degrons to enhance an immune response
WO2025072331A1 (en) 2023-09-26 2025-04-03 Flagship Pioneering Innovations Vii, Llc Cas nucleases and related methods
WO2025076291A1 (en) 2023-10-06 2025-04-10 Bluerock Therapeutics Lp Engineered type v rna programmable endonucleases and their uses
WO2025073890A1 (en) 2023-10-06 2025-04-10 Institut National de la Santé et de la Recherche Médicale Method to capture circulating tumor extracellular vesicles
WO2025093665A1 (en) 2023-10-31 2025-05-08 BioNTech SE Particles, compositions and methods
WO2025096807A2 (en) 2023-10-31 2025-05-08 Flagship Pioneering Innovations Vii, Llc Novel therapeutic dna forms
US20250162981A1 (en) 2023-11-14 2025-05-22 Flagship Pioneering Innovations Vii, Llc Ionizable lipidoid compositions and therapeutic uses thereof
WO2025106754A1 (en) 2023-11-15 2025-05-22 BioNTech SE Coronavirus vaccine
JP2025097909A (ja) 2023-11-15 2025-07-01 ビオンテック・ソシエタス・エウロパエア Ｓａｒｓ－ｃｏｖ－２免疫原性組成物
US20250161347A1 (en) 2023-11-22 2025-05-22 Flagship Pioneering Innovations Vii, Llc Methods and compositions for treating non-alcoholic fatty liver disease
WO2025117877A2 (en) 2023-12-01 2025-06-05 Flagship Pioneering Innovations Vii, Llc Cas nucleases and related methods
WO2025124560A1 (zh) * 2023-12-13 2025-06-19 上海瑞宏迪医药有限公司 用于递送治疗剂的组合物和化合物
WO2025124711A1 (en) 2023-12-13 2025-06-19 BioNTech SE Glycolipid compositions
WO2025126071A1 (en) 2023-12-14 2025-06-19 Pfizer Inc. Rna molecules
WO2025134062A2 (en) 2023-12-21 2025-06-26 Biontech Delivery Technologies Gmbh Ionizable lipids
WO2025134066A1 (en) 2023-12-21 2025-06-26 Biontech Delivery Technologies Gmbh Ionizable lipids
WO2025133105A1 (en) 2023-12-21 2025-06-26 Biontech Delivery Technologies Gmbh Compositions and methods
WO2025149492A1 (en) 2024-01-08 2025-07-17 BioNTech SE Rna encoding an immune inhibitory il-1 family member
WO2025157848A1 (en) 2024-01-23 2025-07-31 Institut National de la Santé et de la Recherche Médicale Methods for the intravenous treatment of sanfilippo syndrome type iiib
WO2025160334A1 (en) 2024-01-26 2025-07-31 Flagship Pioneering Innovations Vii, Llc Immunoreceptor inhibitory proteins and related methods
WO2025166325A1 (en) 2024-02-02 2025-08-07 Editas Medicine, Inc. MODIFIED GUIDE RNAs
WO2025186725A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Improved lnp formulations and uses thereof
WO2025186293A1 (en) 2024-03-06 2025-09-12 Institut National de la Santé et de la Recherche Médicale Chmp2b mutants for use for treating infection
WO2025194019A1 (en) 2024-03-14 2025-09-18 Flagship Pioneering Innovations Vii, Llc Methods for treating liver fibrosis and non-alcoholic fatty liver disease
WO2025202937A1 (en) 2024-03-26 2025-10-02 BioNTech SE Cancer vaccines
WO2025202213A1 (en) 2024-03-26 2025-10-02 Institut National de la Santé et de la Recherche Médicale Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells
WO2025213138A1 (en) 2024-04-05 2025-10-09 Editas Medicine, Inc. Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma
WO2025213131A1 (en) 2024-04-05 2025-10-09 BioNTech SE Rna compositions for delivery of orthopox antigens and related methods
WO2025217275A2 (en) 2024-04-10 2025-10-16 Flagship Pioneering Innovations Vii, Llc Immune cell targeted compositions and related methods
CN118319880B (zh) * 2024-04-15 2025-02-07 荣灿生物医药技术(上海)有限公司 靶向肺部高效递送核酸的脂质纳米颗粒、吸入式制剂及应用
WO2025224684A1 (en) 2024-04-24 2025-10-30 BioNTech SE Compositions and methods for producing engineered immune cells
WO2025228975A1 (en) 2024-04-29 2025-11-06 BioNTech SE Particles, compositions and methods
WO2025229572A1 (en) 2024-05-01 2025-11-06 Glaxosmithkline Biologicals Sa Epstein-barr virus antigen-encoding messenger ribonucleic acid and antigen protein vaccines
US20250353881A1 (en) 2024-05-16 2025-11-20 Flagship Pioneering Innovations Vii, Llc Immunoreceptor inhibitory proteins and related methods
WO2025245188A2 (en) 2024-05-21 2025-11-27 Flagship Pioneering Innovations Vii, Llc Methods of treating liver steatosis and non-alcoholic fatty liver disease
WO2025245111A1 (en) 2024-05-22 2025-11-27 Flagship Pioneering Innovations Vii, Llc Immunoreceptor targeting proteins and related methods
WO2025264662A1 (en) 2024-06-18 2025-12-26 BioNTech SE Compositions and methods for treatment of melanoma
WO2025262460A1 (en) 2024-06-21 2025-12-26 BioNTech SE Lipid compositions for nucleic acid delivery
WO2026005944A1 (en) 2024-06-24 2026-01-02 Avanti Polar Lipids, Llc Piperazine based divalent ionizable lipids and their uses
WO2026006196A1 (en) 2024-06-24 2026-01-02 Avanti Polar Lipids, Llc Conical shaped diacyl glyceroethylphosphocholines as cationic lipids and uses thereof
WO2026006577A1 (en) 2024-06-26 2026-01-02 Flagship Pioneering Innovations Vii, Llc Therapeutic circular dna forms
WO2026015882A1 (en) 2024-07-12 2026-01-15 BioNTech SE Hsv antigen fragments and related methods
WO2026018181A1 (en) 2024-07-17 2026-01-22 Pfizer Inc. Immunogenic compositions and uses thereof
WO2026018213A1 (en) 2024-07-18 2026-01-22 Vaxthera Sas A broadly protective mosaic vaccine against highly pathogenic avian influenza viruses
WO2026021698A1 (en) 2024-07-23 2026-01-29 BioNTech SE Nucleic acid particle
WO2026037391A1 (en) * 2024-08-16 2026-02-19 Shanghai Vitalgen Biopharma Co., Ltd. Compositions and methods for Antigen-presenting cell-specific delivery of nucleic acids
WO2026041793A1 (en) 2024-08-23 2026-02-26 BioNTech SE Chimeric proteins comprising non-human protein domains for enhancing antigenicity
WO2026047603A1 (en) 2024-08-28 2026-03-05 BioNTech SE Sars-cov-2 immunogenic compositions
WO2026047153A1 (en) 2024-08-28 2026-03-05 BioNTech SE Potency assay for multiple coding nucleic acids
WO2026047148A1 (en) 2024-08-29 2026-03-05 BioNTech SE Minimal polypeptide-encoding rnas
WO2026055543A1 (en) 2024-09-06 2026-03-12 Flagship Pioneering Innovations Vii, Llc Modified dna compositions and related methods
WO2026055547A1 (en) 2024-09-06 2026-03-12 Flagship Pioneering Innovations Vii, Llc Dna compositions and related methods
WO2026057625A1 (en) 2024-09-11 2026-03-19 BioNTech SE Peptidoglycan hydrolases having a chap domain with engineered active site
WO2026057626A1 (en) 2024-09-11 2026-03-19 BioNTech SE Peptidoglycan hydrolases having multiple enzymatically active domains

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197553B1 (en) 1994-07-15 2001-03-06 Merck & Co., Inc. Method for large scale plasmid purification
JP3556323B2 (ja) 1995-06-15 2004-08-18 富士通株式会社 中継装置
US5965542A (en) 1997-03-18 1999-10-12 Inex Pharmaceuticals Corp. Use of temperature to control the size of cationic liposome/plasmid DNA complexes
WO1999009076A1 (en) 1997-08-15 1999-02-25 Chisso Corporation Polydisperse propylene polymer and process for producing the same
JP2002502831A (ja) 1998-02-03 2002-01-29 イネックス ファーマシューティカルズ コーポレイション 癌の治療に用いる血清に対して安定なプラスミド脂質粒子の全身供与
US6410328B1 (en) 1998-02-03 2002-06-25 Protiva Biotherapeutics Inc. Sensitizing cells to compounds using lipid-mediated gene and compound delivery
US6211140B1 (en) 1999-07-26 2001-04-03 The Procter & Gamble Company Cationic charge boosting systems
DE60334618D1 (de) 2002-06-28 2010-12-02 Protiva Biotherapeutics Inc Verfahren und vorrichtung zur herstellung von liposomen
KR101168440B1 (ko) 2003-07-16 2012-07-27 프로티바 바이오쎄라퓨틱스, 인코포레이티드 지질 캡슐화된 간섭 ｒｎａ
US6927663B2 (en) 2003-07-23 2005-08-09 Cardiac Pacemakers, Inc. Flyback transformer wire attach method to printed circuit board
NZ581166A (en) 2003-09-15 2011-06-30 Protiva Biotherapeutics Inc Polyethyleneglycol-modified lipid compounds and uses thereof
ATE536418T1 (de) 2004-06-07 2011-12-15 Protiva Biotherapeutics Inc Lipidverkapselte interferenz-rna
CA2569645C (en) 2004-06-07 2014-10-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use
CN101267805A (zh) 2005-07-27 2008-09-17 普洛体维生物治疗公司 制造脂质体的系统和方法
EP2224912B1 (en) 2008-01-02 2016-05-11 TEKMIRA Pharmaceuticals Corporation Improved compositions and methods for the delivery of nucleic acids
PL2279254T3 (pl) 2008-04-15 2017-11-30 Protiva Biotherapeutics Inc. Nowe preparaty lipidowe do dostarczania kwasów nukleinowych
CA3029724A1 (en) 2008-11-10 2010-05-14 Muthiah Manoharan Lipids and compositions for the delivery of therapeutics
EP2391343B1 (en) * 2009-01-29 2017-03-01 Arbutus Biopharma Corporation Improved lipid formulation for the delivery of nucleic acids
US8569256B2 (en) 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
WO2011000107A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
EP2496700B1 (en) 2009-11-04 2017-03-01 The University Of British Columbia Nucleic acid-containing lipid particles and related methods
WO2011066651A1 (en) 2009-12-01 2011-06-09 Protiva Biotherapeutics, Inc. Snalp formulations containing antioxidants
AU2010328336B2 (en) 2009-12-07 2017-03-02 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
EP2512449B1 (en) 2009-12-18 2019-08-07 The University of British Columbia Methods and compositions for delivery of nucleic acids
JP2013527856A (ja) 2010-05-12 2013-07-04 プロチバ バイオセラピューティクス インコーポレイティッド 陽イオン性脂質およびその使用方法
NZ605079A (en) 2010-06-03 2015-08-28 Alnylam Pharmaceuticals Inc Biodegradable lipids for the delivery of active agents
WO2012016184A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
US8466122B2 (en) 2010-09-17 2013-06-18 Protiva Biotherapeutics, Inc. Trialkyl cationic lipids and methods of use thereof
JP5902197B2 (ja) 2011-01-11 2016-04-13 アルニラム・ファーマシューティカルズ・インコーポレーテッド Ｐｅｇ化脂質および薬剤送達のためのそれらの使用
US8710200B2 (en) * 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
US8691750B2 (en) 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
WO2013016058A1 (en) 2011-07-22 2013-01-31 Merck Sharp & Dohme Corp. Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery
JP6250543B2 (ja) 2011-09-27 2017-12-20 アルニラム・ファーマシューティカルズ・インコーポレーテッド ジ脂肪族置換ｐｅｇ化脂質
US8762704B2 (en) 2011-09-29 2014-06-24 Apple Inc. Customized content for electronic devices
WO2013086373A1 (en) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
CA2856737C (en) 2011-12-07 2023-09-26 Alnylam Pharmaceuticals, Inc. Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents
CA3165769A1 (en) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
RU2649364C2 (ru) 2011-12-16 2018-04-02 Модерна Терапьютикс, Инк. Составы на основе модифицированного нуклеозида, нуклеотида и нуклеиновой кислоты
US9415109B2 (en) 2012-07-06 2016-08-16 Alnylam Pharmaceuticals, Inc. Stable non-aggregating nucleic acid lipid particle formulations
CN105164102B (zh) 2013-03-08 2017-12-15 诺华股份有限公司 用于传递活性成分的脂质和脂质组合物
EP3556353A3 (en) * 2014-02-25 2020-03-18 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
PT3766916T (pt) 2014-06-25 2022-11-28 Acuitas Therapeutics Inc Novos lípidos e formulações de nanopartículas lipídicas para distribuição de ácidos nucleicos
JP6778175B2 (ja) * 2014-07-16 2020-10-28 ノバルティス アーゲー 脂質ナノ粒子ホスト中に核酸を封入する方法
WO2016071857A1 (en) 2014-11-07 2016-05-12 Protiva Biotherapeutics, Inc. Compositions and methods for silencing ebola virus expression
EP3289083A4 (en) * 2015-04-27 2018-12-19 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
HRP20240865T1 (hr) 2015-06-29 2024-10-11 Acuitas Therapeutics Inc. Lipidi i formulacije lipidnih nanočestica za isporuku nukleinskih kiselina
WO2017075531A1 (en) 2015-10-28 2017-05-04 Acuitas Therapeutics, Inc. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2017117528A1 (en) * 2015-12-30 2017-07-06 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
CN109152735B (zh) * 2016-05-09 2022-03-11 阿斯利康(瑞典)有限公司 包含亲脂性抗炎剂的脂质纳米颗粒及其使用方法

Also Published As

Publication number Publication date
EP3532103A1 (en) 2019-09-04
EP4714454A2 (en) 2026-03-25
WO2018081480A1 (en) 2018-05-03
EP3532103B1 (en) 2025-12-03
FI3532103T3 (fi) 2026-02-26

Similar Documents

Publication Publication Date Title
DK3532103T3 (da) Formuleringer af lipid-nanopartikler
IL289084A (en) Cannabinoid formulations
IL268697A (en) Formulations
DK3688162T3 (da) Formuleringer
IL249197A0 (en) Stable cannabinoid formulations
DK3473270T5 (da) Konjugat af antistof-lægemiddel
DK3509581T3 (da) Formuleringer af (r)-2-amino-3-phenylpropylcarbamat
PT4070788T (pt) Formulações farmacêuticas
IL281425A (en) Nanoparticle formulations
EP2968137A4 (en) EMULSION FORMULATIONS
IL262574B (en) Cationic lipid
EP3364945C0 (en) SOLID FORMULATION
DK3474822T3 (da) Formuleringer af brincidofovir
PL3541200T3 (pl) Formulacje proszkowe
EP3558864A4 (en) NANOPARTICLES
DK3481420T3 (da) Antistofformuleringer
EP3960158C0 (en) AMLODIPINE FORMULATIONS
MA44987A (fr) Formulations de médicaments améliorées
EP3351561A4 (en) ADRENOMEDULLINE DERIVATIVES WITH LONG-TERM EFFECT
HUE063178T2 (hu) Kopanlizib formulációi
DK3280447T3 (da) Farmaceutiske formuleringer
DK3576719T3 (da) Misbrugsafskrækkende formuleringer på basis af amfetamin
EP3512503A4 (en) Liposomal formulations
IL272167A (en) Hemopexin formulations
EP3478296A4 (en) PHOSOPHOLIPID COMPOSITIONS